Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome

2002 ◽  
Vol 37 (5) ◽  
pp. 765-769 ◽  
Author(s):  
J. Sham ◽  
G. Martin ◽  
J.B. Meddings ◽  
D.L. Sigalet
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Rat Model ◽  
Short Bowel ◽  
Nutritional Outcome ◽  
Epidermal Growth

scholarly journals Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome

2017 ◽  
Vol 312 (4) ◽  
pp. G390-G404 ◽  
Author(s):  
David W. Lim ◽  
Crystal L. Levesque ◽  
Donna F. Vine ◽  
Mitsuru Muto ◽  
Jacob R. Koepke ◽  
...  
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Intestinal Adaptation ◽  
Villus Height ◽  
Short Bowel ◽  
Intestinal Length ◽  
Epidermal Growth ◽  
Glucagon Like Peptide

Glucagon-like peptide-2 (GLP-2) and epidermal growth factor (EGF) treatment enhance intestinal adaptation. To determine whether these growth factors exert synergistic effects on intestinal growth and function, GLP-2 and EGF-containing media (EGF-cm) were administered, alone and in combination, in neonatal piglet models of short bowel syndrome (SBS). Neonatal Landrace-Large White piglets were block randomized to 75% midintestinal [jejunoileal (JI) group] or distal intestinal [jejunocolic (JC) group] resection or sham control, with 7-day infusion of saline (control), intravenous human GLP-2 (11 nmol·kg−1·day−1) alone, enteral EGF-cm (80 μg·kg−1·day−1) alone, or GLP-2 and EGF-cm in combination. Adaptation was assessed by intestinal length, histopathology, Üssing chamber analysis, and real-time quantitative PCR of intestinal growth factors. Combined EGF-cm and GLP-2 treatment increased intestinal length in all three surgical models ( P < 0.01). EGF-cm alone selectively increased bowel weight per length and jejunal villus height in the JI group only. The JC group demonstrated increased intestinal weight and villus height ( P < 0.01) when given either GLP-2 alone or in combination with EGF-cm, with no effect of EGF-cm alone. Jejunal permeability of mannitol and polyethylene glycol decreased with combination therapy in both SBS groups ( P < 0.05). No difference was observed in fat absorption or body weight gain. IGF-1 mRNA was differentially expressed in JI vs. JC piglets with treatment. Combined treatment with GLP-2 and EGF-cm induced intestinal lengthening and decreased permeability, in addition to the trophic effects of GLP-2 alone. Our findings demonstrate the benefits of novel combination GLP-2 and EGF treatment for neonatal SBS, especially in the JC model representing most human infants with SBS. NEW & NOTEWORTHY Glucagon-like peptide-2 (GLP-2) and epidermal growth factor (EGF) are intestinotrophic, with demonstrated benefit in both animal models and human studies of short bowel syndrome (SBS). The current research shows that over and above known trophic effects, the combination of GLP-2 and EGF synergistically lengthens the bowel in neonatal piglet models of SBS. Most notable benefit occurred with resection of the terminal ileum, the common clinical anatomy seen in neonatal SBS and associated with least de novo lengthening postsurgery.

A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome

2005 ◽  
Vol 40 (5) ◽  
pp. 763-768 ◽  
Author(s):  
David L. Sigalet ◽  
Gary R. Martin ◽  
J. Decker Butzner ◽  
Andre Buret ◽  
Jonathan B. Meddings
Keyword(s):  
Pilot Study ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Short Bowel ◽  
Epidermal Growth

A pilot study of the use of epidermal growth factor in treating pediatric short bowel syndrome

2003 ◽  
Vol 124 (4) ◽  
pp. A430
Author(s):  
David Sigalet ◽  
Gary Martin ◽  
Jon Meddings ◽  
Andre Buret ◽  
James Hardin ◽  
...  
Keyword(s):  
Pilot Study ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Short Bowel ◽  
Epidermal Growth

Effect of growth hormone, epidermal growth factor, and insulin on bacterial translocation in experimental short bowel syndrome

2000 ◽  
Vol 35 (5) ◽  
pp. 692-695 ◽  
Author(s):  
I. Eizaguirre ◽  
P. Aldazabal ◽  
M.J. Barrena ◽  
J.M. Garcia-Arenzana ◽  
C. Ariz ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Bacterial Translocation ◽  
Short Bowel ◽  
Epidermal Growth

Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model

2002 ◽  
Vol 282 (1) ◽  
pp. G156-G164 ◽  
Author(s):  
Bohuslav Dvorak ◽  
Melissa D. Halpern ◽  
Hana Holubec ◽  
Catherine S. Williams ◽  
Debra L. McWilliam ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Mrna Expression ◽  
Necrotizing Enterocolitis ◽  
Rat Model ◽  
Transforming Growth Factor ◽  
Gastrointestinal Disease ◽  
Neonatal Rat ◽  
Epidermal Growth ◽  
Neonatal Rat Model

Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease of prematurely born infants. Maternal milk plays an important protective role against NEC development and is the major source of epidermal growth factor (EGF) for neonates. The aim of this study was to examine the effect of orally administered EGF on the incidence of NEC in a neonatal rat model. Newborn rats were artificially fed either with growth factor-free rat milk substitute (RMS) or RMS supplemented with 500 ng/ml of EGF (RMS+EGF). Experimental NEC was induced by exposure to asphyxia and cold stress. Development of NEC was evaluated by gross and histological scoring of damage in the ileum. Ileal EGF receptor (EGF-R), EGF, and transforming growth factor-α mRNA expression was assessed by RT competitive-PCR, and the EGF-R was localized by immunohistochemistry. EGF supplementation of formula reduced the incidence and severity of NEC in rats (13/16 RMS vs. 4/13 RMS+EGF). Ileal EGF-R mRNA expression was markedly increased in the RMS group compared with RMS+EGF. Enhanced EGF-R expression in the RMS group was localized predominantly in the epithelial cells of injured ileum. These data suggest a new potential therapeutic approach for the prevention and treatment of NEC.

Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis

Peptides ◽  
2004 ◽  
Vol 25 (5) ◽  
pp. 793-801 ◽  
Author(s):  
A.J FitzGerald ◽  
M Pu ◽  
T Marchbank ◽  
B.R Westley ◽  
F.E.B May ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Rat Model ◽  
Synergistic Effects ◽  
Trefoil Factor ◽  
Epidermal Growth ◽  
Trefoil Factor Family

Keratinocyte Growth Factor Enhances Early Gut Adaptation in a Rat Model of Short Bowel Syndrome

2000 ◽  
Vol 29 (1) ◽  
pp. 17-27 ◽  
Author(s):  
Will F. Johnson ◽  
Christopher R. DiPalma ◽  
Thomas R. Ziegler ◽  
Sheila Scully ◽  
Catherine L. Farrell
Keyword(s):  
Growth Factor ◽  
Short Bowel Syndrome ◽  
Rat Model ◽  
Keratinocyte Growth Factor ◽  
Short Bowel

Keratinocyte growth factor (KGF) enhances early regrowth in a rat model of short bowel syndrome

1998 ◽  
Vol 114 ◽  
pp. A886 ◽  
Author(s):  
W.F. Johnson ◽  
C.R. DiPalma ◽  
T.R. Ziegler ◽  
C.L. Farrell
Keyword(s):  
Growth Factor ◽  
Short Bowel Syndrome ◽  
Rat Model ◽  
Keratinocyte Growth Factor ◽  
Short Bowel
Sign in / Sign up

Export Citation Format

Share Document